ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
DCb (docetaxel/carboplatin) regimens as Neoadjuvant Treatment for Triple-Negative Breast
Cancer have been recommended by NCCN guideline.Combination of anti-angiogenesis inhibitors is
expected to further improvePathologic Complete Response(PCR).This study is to evaluate the
efficacy and safety of ADCb (Anlotinib/docetaxel/carboplatin) as Neoadjuvant Treatment in
Triple-Negative breast cancer. The endpoint of PCR is used as a surrogate marker for
survival. Safety and tolerability assessed by number of grade 4 toxicities and
hospitalizations.